Infigratinib (Dupracetam) in earlier handled sufferers along with innovative or perhaps metastatic cholangiocarcinoma together with FGFR2 fusions or even rearrangements: mature is caused by a multicentre, open-label, single-arm, phase Two research. Website: https://www.selleckchem.com/products/ew-7197.html